Bounced from 1.01 52wk lows, Now showing support @1.18 Shorts seems to cover, Next Leg Up, EVOK type of gap to fill. NASDAQ:TKAI
Problems were of course apparent in 2015, but to examine Acasti's downfall, you can look as far back as 2013 where the company took a huge plunge.
Horizontal movement this stock looks good for swing and position trades. Or as an option trade straddles and strangles. However one interesting aspect is that the OBV is in a trend upward, precluding an long run trend.
Extremely favourable risk reward trade. Stoploss at 503, just above 200 week moving average. Extremely important level for any stock. It has broken the resistance level of 500 and may soon breach 100 DMA. First target is 540 and second target is 576. This trade does derive comfort from the general breakout of pharma sector in India.
Stock insanely undervalued with Belviq and a great board! Biotechs tend to perform well in bear markets. I will create a google drive for company models, so that everyone has access. 1.50 is a great price to buy more if you are already in this GL www.tradingsignalreviews.com
Money flow is at the lowest point of 2016 attract
As per Elliot Wave, 5 wave correction has been completed at 580 levels and now I expect to see 3 corrective waves before it continues on to its downtrend. Markets in all indices show similar charts, and I believe the markets are ready for a short term corrective upward move. Risk Reward: 1:5 Target 1: 609-620 Stop Loss:570
VRX may, at first glance, look like the bloodshed is over and is moving to recovery. Not just yet. The daily MACD and StochRSI are inching toward sell indicators (see screenshot) and despite the markets upward movements today (Mon 12/14), VRX's recovery was pretty modest as more shareholders exit as they see the fall incoming. Bottom line: Put options are a...
Johnson & Johnson has seen extreme price consolidation since last November. Since they are a highly diversified healthcare company, currency translations affect their bottom line quite substantially. With the recent contraction of the US Dollar, Johnson & Johnson has broken out of a prolonged trading range. If the dollar continues to contract against other foreign...
We seem to be getting a cup and handle forming in LCI at the moment, a classic pattern favored by the O'Neil school of thought. In my book this is an excellent company going for a good price, and with current merger and acquisition activity in the sector I think it has a catalyst for investor interest. When a stock hits 50 on the Twiggs Momentum scale (50 day or...
Due to worse than expected ER, and lowered guidance, and top of all failed $AGN acquisition, it is very possible that $VRX is going to $90-$100 price level. Company is not profitable and even if their international profits rise (mostly Russia and Europe), there are problems in creating sustainable growth.
Boy, does VRX have shtty fundamental, but interesting technicals. I used to hate geometry when I was in high school, but it looks like it finally paid off. I used dotted line to visualize the way that VRX could've gone if the Allergan deal doesn't exist. VRX rallied 1000% in the last 4 years, the Allergan deal is like a life support machine for Valeant right...